As expected from previous studies of PTEN KO prostate cancer models [20], we found that this cancer cell line was not AR-dependent, as it did not respond to enzalutamide in vivo when implanted subcutaneously in the flank of C57BL/6 males (Figure 3a). Here, PTEN is linked to prostate carcinoma.